SignalFDA/Bio

NOVARTIS HALTS AUTOIMMUNE CAR-T TRIALS FOLLOWING THREE PATIENT DEATHS: WSJ - SEEKINGALPHA

Safety halt after three deaths signals major clinical setback for autoimmune CAR-T.

What changed

Safety halt after three deaths signals major clinical setback for autoimmune CAR-T.

Why it matters

Safety halt after three deaths signals major clinical setback for autoimmune CAR-T. — impact context not separately stored; see What changed.

Sources